Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.hest.2021.06.005 http://scihub22266oqcxt.onion/10.1016/j.hest.2021.06.005 34250455!8256660!34250455     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34250455&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Brain+Hemorrhages 2021 ; 2 (4): 151-152 Nephropedia Template TP {{tp|p=34250455|t=2021. Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19 |pdf=|usr=}}{{34250455}} gab.com Text Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19 JO: Brain Hemorrhages http://www.kidney.de/pget.php?&tw=1&pmid=34250455 #FOAvip OBJECTIVES: Intracerebral hemorrhage/bleeding (ICH) after an infection with SARS-CoV-2 (COVID-19) treated with the Janus-kinase inhibitor baricitinib has not been reported. CASE PRESENTATION: A 86yo Caucasian female suddenly developed aphasia with a systolic blood pressure of 220 mmHg. Cerebral imaging revealed an ICH in the left temporal lobe without mass effect and no need for neurosurgical intervention. Her previous history was positive for arterial hypertension, hyperlipidemia, heart failure, renal insufficiency, hyperuricemia, macula degeneration, lumbalgia, and glaucoma bilaterally. Additionally, she had experienced an infection with SARS-CoV-2 with onset 44 days earlier having been treated with ceftriaxone (2 g/d for 7 d), dexamethasone (6 mg for 6 d), and bariticinib (2 mg for 6 d). CONCLUSIONS: Though ICH was time-linked to COVID-19, a causal relation could not be unequivocally established. Whether baricitinib increased the bleeding risk remains speculative. As long as causalities between ICH and baricitinib remain unproven, it should be given with caution and only under close blood pressure monitoring. Twit Text FOAVip Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19 ????Brain Hemorrhages http://www.kidney.de/pget.php?&tw=1&pmid=34250455 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34250455 #FOAvip English Wikipedia <ref>{{Cite pmid|34250455}}</ref> Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19 #MMPMID34250455 Finsterer J; Scorza FA Brain Hemorrhages 2021[Dec]; 2 (4): 151-152 PMID34250455show ga OBJECTIVES: Intracerebral hemorrhage/bleeding (ICH) after an infection with SARS-CoV-2 (COVID-19) treated with the Janus-kinase inhibitor baricitinib has not been reported. CASE PRESENTATION: A 86yo Caucasian female suddenly developed aphasia with a systolic blood pressure of 220 mmHg. Cerebral imaging revealed an ICH in the left temporal lobe without mass effect and no need for neurosurgical intervention. Her previous history was positive for arterial hypertension, hyperlipidemia, heart failure, renal insufficiency, hyperuricemia, macula degeneration, lumbalgia, and glaucoma bilaterally. Additionally, she had experienced an infection with SARS-CoV-2 with onset 44 days earlier having been treated with ceftriaxone (2 g/d for 7 d), dexamethasone (6 mg for 6 d), and bariticinib (2 mg for 6 d). CONCLUSIONS: Though ICH was time-linked to COVID-19, a causal relation could not be unequivocally established. Whether baricitinib increased the bleeding risk remains speculative. As long as causalities between ICH and baricitinib remain unproven, it should be given with caution and only under close blood pressure monitoring. ?Intracerebral bleeding after Janus-kinase inhibitor baricitinib for CO(epmc).pdf DeepDyve Pubget Overpricing